首頁 › 瀰漫性內生性橋腦膠質瘤 › 德克薩斯州 › Houston
Houston, TX 的 瀰漫性內生性橋腦膠質瘤 臨床試驗
10 項針對 瀰漫性內生性橋腦膠質瘤 的研究正在 Houston(約 30 英里範圍內)及其周邊地點尋找參與者。開啟研究以查看參與資格及聯絡研究團隊的方式。
官方研究文本(英文)
正在為研究招募對象嗎?將此頁面置頂展示 — $99 / 30 天 →
ACT001 for the Treatment of Diffuse Intrinsic Pontine Gliomas and H3K27-altered High Grade Gliomas
招募中2 期
- Texas Children's Hospital, Houston
CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
招募中1/2 期
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
Engineered HSV-1 M032 for the Treatment of Children and Adults With Newly Diagnosed Diffuse Midline Glioma After Standard of Care Radiation
招募中1 期
- The University of Texas M. D. Anderson Cancer Center, Houston
Targeted Pediatric High-Grade Glioma Therapy
招募中觀察性研究
- Texas Children's Hospital, Houston
Study of Olutasidenib and Temozolomide in HGG
招募中2 期
- Texas Children's Hospital, Houston
PEP-CMV Vaccine Targeting CMV Antigen to Treat Newly Diagnosed Pediatric HGG and DIPG and Recurrent Medulloblastoma
招募中2 期
- Texas Children's Hospital, Houston
C7R-GD2.CAR T Cells for Patients With GD2-expressing Brain Tumors (GAIL-B)
招募中1 期
- Texas Children's Hospital, Houston
Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion
招募中早期第 1 期歡迎健康志工
- Texas Children's Hospital, Houston
Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
招募中2 期
- Texas Children's Hospital, Houston
A Pilot Study of Larotrectinib for Newly-Diagnosed High-Grade Glioma With NTRK Fusion
招募中早期第 1 期
- Texas Children's Hospital, Houston
其他城市的 瀰漫性內生性橋腦膠質瘤 試驗
- Washington, DC11 項研究
- Philadelphia, PA10 項研究
- Columbus, OH10 項研究
- Seattle, WA10 項研究
- Cincinnati, OH10 項研究
- Chicago, IL9 項研究
- Durham, NC9 項研究
- Boston, MA9 項研究
- Aurora, CO8 項研究
- Miami, FL6 項研究
- Ann Arbor, MI6 項研究
- St. Louis, MO5 項研究
Houston 的其他研究
- 非小細胞肺癌145 項研究
- 乳癌126 項研究
- 癌症(所有類型)121 項研究
- 轉移性癌症104 項研究
- 大腸直腸癌102 項研究
- 卵巢癌89 項研究
- 急性髓系白血病85 項研究
- 肺癌78 項研究
- 前列腺癌76 項研究
- 子宮內膜癌68 項研究
- 胰臟癌61 項研究
- 黑色素瘤59 項研究
資料來源:ClinicalTrials.gov,擷取日期 2026年10月6日。各研究自行設定資格標準;由研究團隊決定參與者資格。